PRA International (Reston, VA, www.prainternational.com) has completed the acquisition of Pharma Bio-Research (Zuidlaren, The Netherlands), an early-phase clinical development and bioanalytical company.
PRA International (Reston, VA, www.prainternational.com) has completed the acquisition of Pharma Bio-Research (Zuidlaren, The Netherlands), an early-phase clinical development and bioanalytical company. Plans for PRA International to acquire Pharma Bio-Research were originally announced on June 19. The acquisition, valued at 84.6 million Euros, provides PRA International with early-phase development and bioanalytical laboratory facilities in Europe. PRA also expects to draw on Pharma Bio-Research’s expertise to establish drug development laboratory facilities in the US for biotech and pharmaceutical clients.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.